Our Process

There is no single treatment that is appropriate for every patient. Active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, targeted treatment, and radiopharmaceutical therapy may each have a role depending on the cancer's risk category, stage, molecular characteristics, age, health, and patient preferences.

Robotic-assisted radical prostatectomy is an established minimally invasive surgical approach performed by appropriately trained urologic surgeons. As with any major surgery, it has potential risks, including bleeding, infection, urinary incontinence, and erectile dysfunction. Individual risks depend on the patient's condition and surgical factors.

PSA testing is an important component of follow-up after definitive treatment. Changes in PSA levels can help specialists evaluate treatment response and identify possible biochemical recurrence, although interpretation depends on the type of treatment previously received.

Hormone therapy may be used for locally advanced, recurrent, or metastatic prostate cancer and is often combined with radiation therapy for selected higher-risk localized or locally advanced disease. The exact treatment approach depends on the patient's cancer characteristics.

PSMA-targeted radiopharmaceutical treatment may be considered for selected patients with advanced prostate cancer whose tumors demonstrate appropriate PSMA expression and who meet other clinical eligibility requirements. Specialist evaluation and appropriate imaging are required before treatment.

Yes. Vanya Health can facilitate medical record review and specialist consultations, helping international patients understand potential treatment approaches, diagnostic requirements, estimated costs, and treatment planning before making travel arrangements.